A phase 2 trial conducted in China also employed TCR repertoire analysis, in which refractory MSS–metastatic–CRC patients were administered fecal microbiota transplantation, plus an anti-PD-L1 antibody and multi-tyrosine kinase inhibitor, as a third-line treatment [71]. This evidence concerns the gene CD274 and colorectal carcinoma.